Updated on 13 April 2012
In addition to culturing the tumor samples, the genomic component of the tumor is also thoroughly profiled at Mitra Biotech. This data is further being used to aid in the drug discovery process as well. Mitra Biotech is in collaboration with pharma companies for the development of three anti-cancer molecules. They are trying to determine the specific epigenetic markers and gene signatures against which the drug molecules are effective. This will not only save money but also valuable time for the companies.
Even though it currently offers personalized services to cancer patients, Dr Sundaram insists that Mitra Biotech is not a services company, but rather a discovery company, which is developing novel innovative technologies to help combat cancer. This platform has so far been validated in over 400 patients clinically and the founders plan to continue work for the next few years till they have over 2,000 clinical validations. This data can then be presented to the FDA for approval, paving the way for revolutionizing cancer treatments.